Pamidronate disodium salt hydrate
SIGMA/P2371 - ≥95% (NMR), solid
Synonym: 3-
CAS Number: 57248-88-1 (anhydrous)
Empirical Formula (Hill Notation): C3H9NO7P2Na2 · xH2O
Molecular Weight: 279.03 (anhydrous basis)
EC Number: 260-647-1
MDL Number: MFCD11045314
Linear Formula: C3H9NO7P2Na2 · xH2O
Product Type: Chemical
| assay | ≥95% (NMR) |
| color | white |
| form | solid |
| InChI | 1S/C3H11NO7P2.2Na.H2O/c4- |
| InChI key | TVQNUQCYOOJTMK-UHFFFAOYSA |
| mp | 300 °C |
| originator | Novartis |
| Quality Level | 100 ![]() |
| SMILES string | O.[Na+].[Na+].NCCC(O)(P(O |
| solubility | H2O: 28 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM). |
| Biochem/physiol Actions: | Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth. |
| Features and Benefits: | This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 100 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (NMR) |
| mp | 300 °C |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


